Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by askretkaon Jun 25, 2023 1:27am
261 Views
Post# 35513396

RE:90 days

RE:90 daysRoche is the most likely candidate,  but Merck did a  Pancreatic study first and had ok results but it was considered a failure, 42% ? achieved stable disease I think but I don't think they filled the trial either?  Matt said he got a call as trial kept going and some of Patients were " Still alive" That was mentioned in one of quarterly reports quite awhile ago, before Roche's Goblet was started.
 
The intresting thing here is the Merck trial DIDN'T have Chemo like the Roche Goblet study did. If you check latest ONC presentation that fact is UNDERLINED.
So one has to wonder if Merck wants in with Keytruda  Pelareorep and chemo. I kinda think Merck is going the
Pancreatic vaccine route as they made a deal with Moderna. 

There's a recent Nature article with some promising new Pancreatic cancer vaccine results.  They had 16 patients.  They had to have surgery first. Only 20% of Pancreatic Cancer  patients are eligible for surgery so that leaves out 80% of patients for now.  Then they used a biopsy of surgery to produce a personalized vaccine. Only 8 of 16 responded to vaccine.  Some of patients had their spleen removed so they think that might have had something to do with only 8 responses. Your spleen plays a role in your immune system. 

You can live a pretty normal life without your spleen but you're more susceptible to infections for the rest of your life. 

With this in mind I'd say Avantage Pelareorep!

Cheers!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!




<< Previous
Bullboard Posts
Next >>